Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» FSHD
FSHD
Early data for Avidity's RNA therapy show possible functional benefit in muscular dystrophy
Fierce Biotech
Wed, 06/12/24 - 11:19 pm
Avidity Biosciences
RNA
AOC 1020
del-brax
FSHD
clinical trials
Sanofi licenses a preclinical genetic disease drug from an unknown biotech spun out of the NIH
Endpoints
Tue, 10/4/22 - 10:47 am
Sanofi
antibody-RNA conjugate
miRecule
FSHD
Epic Bio, Founded by CRISPR Pioneer, Launches to Revolutionize Genetic Medicine With Epigenetic Engineering
BioSpace
Tue, 07/12/22 - 10:49 am
Epic Bio
CRISPR
CAS protein
FSHD
Fulcrum under pressure on underwhelming losmapimod data in type of muscular dystrophy
Seeking Alpha
Tue, 08/11/20 - 11:39 am
Fulcrum Therapeutics
clinical trials
losmapimod
FSHD
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
CP Wire
Mon, 06/24/19 - 09:32 am
Fulcrum Therapeutics
IPOs
FSHD
sickle cell disease
beta thalassemia
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
Mon, 06/24/19 - 09:29 am
Fulcrum Therapeutics
IPOs
FSHD
sickle cell disease
beta thalassemia
Working with Patients and a Fresh $80M, Fulcrum Eyes a 2019 IPO
Xconomy
Wed, 09/5/18 - 09:30 am
Fulcrum Therapeutics
IPOs
FSHD